Phathom Pharmaceuticals: Superior Efficacy Drives Vonoprazan Growth

Following Phathom's excellent financial results for Q3, its average price target rose to $23.13, which implies an upside of about 58.8% from its current stock price. Phathom Pharmaceuticals raised its full-year 2025 revenue guidance from $165-$175 million to $170-$175 million. The main reason why vonoprazan franchise sales grew by 201% year-on-year to $49.5 million is its superior efficacy compared to PPIs.

Seeking Alpha • Nov 21, 2025

Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)

First patient dosed, with topline results expected in 2027 pHalcon-EoE-201 is the first large, well-controlled clinical trial of an acid secretory treatment in EoE FLORHAM PARK, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced the first patient has been dosed in its Phase 2 pHalcon-EoE-201 clinical trial evaluating VOQUEZNA® (vonoprazan) tablets as an investigational treatment for eosinophilic esophagitis (EoE) in adults.

GlobeNewsWire • Nov 4, 2025

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

FLORHAM PARK, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following upcoming investor conferences: Guggenheim Securities 2nd Annual Healthcare Innovation Conference in Boston, MA Date: Monday, November 10, 2025Live Webcast: 3:00 pm EST Management to participate in one-on-one meetings throughout the conference Stifel 2025 Healthcare Conference in New York, NY Date: Wednesday, November 12, 2025Live Webcast: 4:40 pm EST Management to participate in one-on-one meetings throughout the conference Jefferies Global Healthcare Conference in London, UK Date: Tuesday, November 18, 2025Live Webcast: 9:30 am EST / 2:30 pm GMT Management to participate in one-on-one meetings throughout the conference 16th Annual Craig-Hallum Alpha Select Conference in New York, NY Date: Tuesday, November 18, 2025 Management to participate in one-on-one meetings throughout the conference 8th Annual Evercore Healthcare Conference in Miami, FL Date: Tuesday, December 2, 2025Live Webcast: 3:25 pm EST Management to participate in one-on-one meetings throughout the conference To access the live webcast and archived recordings of each event, visit the News & Events section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations.

GlobeNewsWire • Nov 3, 2025

Phathom Pharmaceuticals, Inc. (PHAT) Q3 2025 Earnings Call Transcript

Phathom Pharmaceuticals, Inc. ( PHAT ) Q3 2025 Earnings Call October 30, 2025 8:00 AM EDT Company Participants Eric Sciorilli - Director of Business Development & Investor Relations Steven Basta - CEO, President & Director Sanjeev Narula - Chief Financial & Business Officer Conference Call Participants Umer Raffat - Evercore ISI Institutional Equities, Research Division Kristen Kluska - Cantor Fitzgerald & Co., Research Division Kyuwon Choi - Goldman Sachs Group, Inc., Research Division Yatin Suneja - Guggenheim Securities, LLC, Research Division Joseph Stringer - Needham & Company, LLC, Research Division Annabel Samimy - Stifel, Nicolaus & Company, Incorporated, Research Division Chase Knickerbocker - Craig-Hallum Capital Group LLC, Research Division Matthew Caufield - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Hello, and welcome to the Phathom Pharmaceuticals' Third Quarter 2025 Earnings Results Call.

Seeking Alpha • Oct 30, 2025

Phathom Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Over 790,000 total VOQUEZNA® prescriptions filled to date Filled VOQUEZNA prescriptions increased 28% from Q2 2025 Net revenues of $49.5 million, up 25% quarter over quarter, and cash operating expenses down 43% quarter over quarter Full-year 2025 revenue guidance updated to $170–$175 million; company expects to achieve operating profitability in 2026 Management to host conference call today, October 30, 2025, at 8:00 a.m. ET FLORHAM PARK, N.J.

GlobeNewsWire • Oct 30, 2025

Phathom Pharmaceuticals, Inc. (PHAT) Reports Q3 Loss, Tops Revenue Estimates

Phathom Pharmaceuticals, Inc. (PHAT) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.3. This compares to a loss of $1.32 per share a year ago.

Zacks Investment Research • Oct 30, 2025

Phathom Pharmaceuticals Announces Publication of Data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA® (vonoprazan) Improved Nocturnal GERD Symptoms in Patients with Non-Erosive Reflux Disease

FLORHAM PARK, N.J., Oct. 25, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that results of additional analyses from its pivotal Phase 3 pHalcon-NERD-301 trial evaluating VOQUEZNA® (vonoprazan) tablets in patients with Non-Erosive Reflux Disease (NERD) have been published in the American Journal of Gastroenterology. The article, titled “Vonoprazan Improves Nocturnal Gastroesophageal Reflux Symptoms in Non-Erosive Reflux Disease”, underscores the significant burden of nighttime GERD symptoms and the potential role of VOQUEZNA in addressing this aspect of the disease.

GlobeNewsWire • Oct 25, 2025

Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting

FLORHAM PARK, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced its participation in the American College of Gastroenterology's (ACG) 2025 Annual Scientific Meeting, being held October 24-29 in Phoenix, Arizona.

GlobeNewsWire • Oct 23, 2025

Phathom Pharmaceuticals to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, October 30, 2025

FLORHAM PARK, N.J., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:00 am EDT on Thursday, October 30, 2025, to report its third quarter 2025 financial results and provide a business update.

GlobeNewsWire • Oct 20, 2025

Phathom Pharmaceuticals Appoints Sanjeev Narula as Chief Financial and Business Officer

Sanjeev Narula brings proven success in scaling commercial-stage biopharma companies with expertise in capital and investor strategies, M&A, and operational excellence Appointment strengthens Phathom's leadership team and ability to execute its growth strategy in GI FLORHAM PARK, N.J., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced the appointment of Sanjeev Narula as Chief Financial and Business Officer.

GlobeNewsWire • Oct 6, 2025